VIP152 + BTKi
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed Non Hodgkin Lymphoma
Conditions
Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Richter Syndrome, MYC Amplification, MYC Overexpression, MYC Translocation
Trial Timeline
Dec 16, 2021 → May 26, 2023
NCT ID
NCT04978779About VIP152 + BTKi
VIP152 + BTKi is a phase 1 stage product being developed by Vincerx Pharma for Relapsed Non Hodgkin Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04978779. Target conditions include Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed Non Hodgkin Lymphoma were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04978779 | Phase 1 | Terminated |
Competing Products
20 competing products in Relapsed Non Hodgkin Lymphoma